China National Medicines Corporation Ltd.

SHSE:600511 Stock Report

Market Cap: CN¥25.8b

China National Medicines Future Growth

Future criteria checks 1/6

China National Medicines is forecast to grow earnings and revenue by 9.1% and 8.8% per annum respectively. EPS is expected to grow by 9.5% per annum. Return on equity is forecast to be 12.8% in 3 years.

Key information

9.1%

Earnings growth rate

9.5%

EPS growth rate

Healthcare earnings growth22.8%
Revenue growth rate8.8%
Future return on equity12.8%
Analyst coverage

Low

Last updated21 Nov 2024

Recent future growth updates

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 25
The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Recent updates

Returns On Capital Signal Tricky Times Ahead For China National Medicines (SHSE:600511)

Dec 01
Returns On Capital Signal Tricky Times Ahead For China National Medicines (SHSE:600511)

We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease

Nov 12
We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 25
The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Sep 26
China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Sep 10
Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Jul 28
Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Jun 24
China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Jun 07
China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Jun 05
Is China National Medicines (SHSE:600511) Using Too Much Debt?

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

May 21
Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

Apr 10
Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

China National Medicines (SHSE:600511) Could Easily Take On More Debt

Feb 28
China National Medicines (SHSE:600511) Could Easily Take On More Debt

Earnings and Revenue Growth Forecasts

SHSE:600511 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202662,3482,688N/A2,8713
12/31/202557,5462,458N/A2,2084
12/31/202452,7662,293N/A1,9023
9/30/202451,1952,1651,5401,688N/A
6/30/202450,3122,1621,6881,827N/A
3/31/202450,5922,1912,0082,151N/A
12/31/202349,6962,1462,5822,727N/A
9/30/202347,4861,9952,4662,602N/A
6/30/202347,6322,0862,0402,194N/A
3/31/202345,6652,0052,4292,560N/A
12/31/202245,4991,9642,2652,395N/A
9/30/202246,7191,8841,3361,460N/A
6/30/202246,3991,8501,0811,185N/A
3/31/202247,1851,8301,7461,851N/A
12/31/202146,4691,7541,8621,957N/A
9/30/202145,5591,6801,0851,170N/A
6/30/202144,9231,5291,1291,197N/A
3/31/202142,5121,4491,1871,247N/A
12/31/202040,3791,3831,2331,302N/A
9/30/202041,0461,5371,0581,125N/A
6/30/202041,1531,4691,9221,997N/A
3/31/202042,8051,5491,3991,477N/A
12/31/201944,6441,6041,6901,776N/A
9/30/201942,6731,5251,0371,139N/A
6/30/201940,9911,5231,0241,159N/A
3/31/201939,6591,436-33103N/A
12/31/201838,7401,404849982N/A
9/30/201837,9941,2562,4572,576N/A
6/30/201837,4521,224N/A2,058N/A
3/31/201836,6531,163N/A1,424N/A
12/31/201736,2851,141N/A1,074N/A
9/30/201736,0721,060N/A63N/A
6/30/201735,5401,044N/A-85N/A
3/31/201740,1031,101N/A488N/A
12/31/201634,611990N/A1,043N/A
9/30/201628,613887N/A461N/A
6/30/201622,813752N/A716N/A
3/31/201612,408527N/A445N/A
12/31/201512,078513N/A440N/A
9/30/201512,065499N/A307N/A
6/30/201511,894499N/A424N/A
3/31/201511,773490N/A394N/A
12/31/201411,538483N/A219N/A
9/30/201411,177465N/A338N/A
6/30/201410,824457N/A240N/A
3/31/201410,408431N/A204N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600511's forecast earnings growth (9.1% per year) is above the savings rate (2.8%).

Earnings vs Market: 600511's earnings (9.1% per year) are forecast to grow slower than the CN market (25.4% per year).

High Growth Earnings: 600511's earnings are forecast to grow, but not significantly.

Revenue vs Market: 600511's revenue (8.8% per year) is forecast to grow slower than the CN market (13.7% per year).

High Growth Revenue: 600511's revenue (8.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600511's Return on Equity is forecast to be low in 3 years time (12.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 19:42
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

China National Medicines Corporation Ltd. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Yanyin ZhuChina International Capital Corporation Limited
Ying LuoChina Merchants Securities Co. Ltd.